Medical/Pharmaceuticals
SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 inAustralia. In the Phase 2a trial of a two stage adaptive design ...
2021-10-25 20:30
1389
Antengene to Host its First R&D Days on November 16 and November 18, 2021
* Virtual Event (in English) on November 16 * On Site Event with Live Webcast (in Mandarin) on Nov 18 SHANGHAI and HONG KONG, Oct. 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, deve...
2021-10-25 20:00
2239
111, Inc. Announces Strategic Partnership with Chugai Pharma China Co., Ltd. to Accelerate Innovations in Chronic Disease Management
SHANGHAI, Oct. 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Chugai Phar...
2021-10-25 19:00
1609
Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
HOUSTON and SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreem...
2021-10-25 17:00
1421
Farrer Park Hospital Offers Transcatheter Aortic Valve Implantation (TAVI)
SINGAPORE, Oct. 25 , 2021 /PRNewswire/ -- Farrer Park Hospital ("FPH") offers TAVI as an alternative treatment option for those suffering from aortic valve stenosis who are elderly or for younger patients who are not suitable for open-heart surgery. In aortic valve stenosis, the aortic valve sit...
2021-10-25 13:09
1998
A Singapore-based HealthTech Startup Redefines Chronic Disease Care with Promising Clinic Acquisition
SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- A HealthTech start-up, HeartVoice announced its acquisition of Integrated Wellness Clinic in Novena Specialist Center. The clinic has been offering Health Screening services for corporate clients since 2015, pioneering this field,having served over 600 cor...
2021-10-25 10:30
2189
NCCN Works with Polish Health Leaders to Improve Cancer Standardization, Coordination, and Outcomes
PLYMOUTH MEETING, Pa., Oct. 25, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—today announced the publication of new NCCN Guidelines® for Cervical Cancer: Poland Edition. This is the organization's most-recent co...
2021-10-25 09:13
2005
Meet the Next Resolution in Medicine -- Polaris Biology Releases Starion™, the next-generation mass cytometer
SHANGHAI, Oct. 23, 2021 /PRNewswire/ -- Polaris Biology, a leading innovator in
single-cell technologies, announced today the largest product launch in company
history with the introduction of the Starion™ Mass Cytometry System.
2021-10-23 15:05
2680
I-Mab Expands U.S. Footprint with New R&D Site in San Diego
- I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growingSan Diego biotech hub - The new site will complement I-Mab's Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US R&...
2021-10-22 20:00
1525
Ping An Good Doctor Unveils Strategic 2.0 Continuum
SHANGHAI, Oct. 22, 2021 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; Stock Code: 01833.HK), the leading online medical and healthcare service platform in China, presented its business achievements and unveiled its Strategic 2.0 Continuum at an investor...
2021-10-22 17:08
1923
2021 Bio-enzyme Application Explorer Summit held in Chengdu
The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...
2021-10-22 14:23
1152
Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with TIGIT monoclonal antibody for the teratment of solid tumors
HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Akeso, one of leading Chinese pharmaceutical innovation company announces that the first patient was dosed in a phase I clinical trial of the Company's independently developed TIGIT monoclonal antibody (AK127) in combination with the Company's global firs...
2021-10-22 09:50
1162
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore
SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withIncyte Biosciences International Sàrl,the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and onc...
2021-10-22 09:00
1497
Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China
SUZHOU, China, Oct. 21 , 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) fo...
2021-10-21 22:33
2039
Speclipse included in MedTech Outlook rating of top 10 non-invasive device companies
SEOUL, South Korea, Oct. 21, 2021 /PRNewswire/ -- Speclipse, a startup
specializing in laser spectroscopic and AI-based medicaldiagnostic technologies
and a member ofBorn2Global Centre, was recently included in MedTech Outlook's
"Top 10 Non InvasiveDevice Companies" ranking for 2021.
2021-10-21 21:00
6157
INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives
Memorandum of Understanding builds on recent regulatory authorization from INVIMAto conduct INNOVATE Phase 3 trial for INO-4800, INOVIO's COVID-19 vaccine candidate,in Colombia Colombia authorization augments recent regulatory authorizations from Brazil, the Philippines and Mexico to commence it...
2021-10-21 20:00
2514
Mentice's CEO Göran Malmberg to present the company's interim report at a webcast conference call on October 28 at 9:30 CEST
STOCKHOLM, Oct. 21, 2021 /PRNewswire/ -- Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFOGunilla Andersson. To register for the presentation of ...
2021-10-21 16:28
1504
Guangzhou Concord Cancer Center Becomes a Designated Hospital of Social Healthcare Insurance
BEIJING, Oct. 21, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone ...
2021-10-21 16:00
8381
Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates
SHANGHAI and HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-10-21 16:00
2611
Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company") , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...
2021-10-21 15:58
1194
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 276 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
7117
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
4663
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
4532